



Commercial/Healthcare Exchange PA Criteria

Effective Date: November 11, 2020

Prior Authorization: Breztri Aerosphere

Products Affected: Breztri (budesonide, glycopyrrolate, and formoterol fumarate) Aerosphere

Medication Description: Breztri Aerosphere contains budesonide, glycopyrrolate, and formoterol fumarate. These drugs represent three different classes of medications (a synthetic corticosteroid, an anticholinergic, and a long-acting selective beta2-adrenoceptor agonist) that have different effects on clinical physiology and inflammatory indices of COPD.

Covered Uses: Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Exclusion Criteria:

1. Treatment of asthma
2. Relief of acute bronchospasm
3. Hypersensitivity to budesonide, glycopyrrolate, formoterol

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Age Restrictions: 18 years of age or older

Prescriber Restrictions: N/A

Coverage Duration: 1 year

Other Criteria:

Chronic obstructive pulmonary disease (COPD)

- A. Patient has a confirmed diagnosis of COPD; **AND**
- B. Patient has had a trial and failure, intolerance, or contraindication to Trelegy Ellipta.

References:

1. Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2020.



Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/2/2020